Tocilizumab-Induced Erythema Annulare Centrifugum
Open Access
- 13 October 2022
- journal article
- research article
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (3) , 302-306
Abstract
We report the case of a 42-year-old woman with rheumatoid arthritis undergoing treatment with subcutaneous tocilizumab for the past 6 months. Three days after the administration, an asymptomatic inflammatory annular plaque of 4 cm with discrete whitish scales at the inner border margin developed at the injection site in the left iliac fossa. A smaller plaque in the left groin appeared soon after. The mycological exam was negative. Histology showed a lymphoplasmacytic superficial and deep perivascular, and periadnexal, dermal infiltrate, without epidermal changes. Lesions spontaneously regressed in 4 months. The diagnosis was clinically and histologically consistent with erythema annulare centrifugum, following the exclusion of other differential diagnoses. Erythema annulare centrifugum represents a delayed-type hypersensitivity reaction generally considered idiopathic or otherwise related to numerous triggers, including drugs such as biologics. We describe the first reported case of tocilizumab-induced erythema annulare centrifugum. This case should alert dermatologists to this relatively rare and complex entity and should raise awareness to cutaneous biologic drug reactions.Keywords
This publication has 9 references indexed in Scilit:
- An observational study of the efficacy of azithromycin in erythema annulare centrifugumClinical and Experimental Dermatology, 2018
- Tocilizumab: A Review in Rheumatoid ArthritisDrugs, 2017
- Clinical variants of pityriasis roseaWorld Journal of Clinical Cases, 2017
- Pityriasis rosea and pityriasis rosea‐like eruption: Can they be distinguished?The Journal of Dermatology, 2014
- Pityriasis rosea‐like arranged eruption after infliximab therapy in a patient with psoriasis vulgarisThe Journal of Dermatology, 2014
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritisTherapeutic Advances in Musculoskeletal Disease, 2010
- Pityriasis rosea: An update with a critical appraisal of its possible herpesviral etiologyJournal of the American Academy of Dermatology, 2009
- Adalimumab‐induced pityriasis roseaJournal of the European Academy of Dermatology and Venereology, 2007
- Scaly signs in dermatologyIndian Journal of Dermatology, Venereology and Leprology, 2006